G
GenSight Biologics
Develops innovative therapies for mitochondrial and neurodegenerative diseases
About GenSight Biologics
GenSight Biologics specializes in developing gene therapy treatments aimed at combating blindness, particularly focusing on neurodegenerative retinal diseases such as Leber Hereditary Optic Neuropathy (LHON). Operating within the biotechnology sector, the company targets patients suffering from vision loss due to genetic disorders. GenSight's business model revolves around advancing clinical trials and securing regulatory approvals to bring their therapies to market. Revenue generation is primarily through the commercialization of their gene therapy products, once approved, and potential partnerships or licensing agreements. The company leverages cutting-edge techniques like mitochondrial targeting sequences and optogenetics to enhance the efficacy of their treatments. By addressing unmet medical needs in the ophthalmology market, GenSight Biologics positions itself as a key player in the gene therapy landscape. Keywords: gene therapy, blindness, retinal diseases, LHON, biotechnology, clinical trials, ophthalmology, mitochondrial targeting, optogenetics, regulatory approvals
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Paris, France
- Listing
- IPO 2016
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 79.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Genetics and genomics, Eye Diseases, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Mar 2026 | $1.9M | — | Invus · UPMC Enterprises · Heights Capital Management | ↗ |
| POST IPO EQUITY✓Other financing | Sep 2025 | $4.1M | — | Heights Capital Management · Alumni Capital · Invus | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for GenSight Biologics is 2.9K monthly website visits, down 17.1% over the last three months. GenSight Biologics's team grew 6.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Index Ventures
Abingworth
Versant Ventures
Novartis Venture Fund
HealthCap
Jennison Associates
Fidelity Investments
Perceptive Advisors
Heights Capital Management
Invus
UPMC Enterprises
Series B and later4 investors entered at this stage
Sofinnova Partners
Kreos Capital
3SBio
Alumni Capital
Other known investors6 additional known investors
CNRS Innovation
French National Centre for Scientific Research - CNRS
SATT LUTECH
Sorbonne University
Agoranov
IBionext
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GenSight Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GenSight Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.